Show simple item record

dc.contributor.authorKhattak, A
dc.contributor.authorRobert, C
dc.contributor.authorBlank, C
dc.contributor.authorMandala, M
dc.contributor.authorLong, G
dc.contributor.authorAtkinson, V
dc.contributor.authorDalle, S
dc.contributor.authorHaydon, A
dc.contributor.authorLichinitser, M
dc.contributor.authorCarlino, M
dc.contributor.authorSandhu, S
dc.contributor.authorLarkin, J
dc.contributor.authorPuig, S
dc.contributor.authorAscierto, P
dc.contributor.authorRutkowski, P
dc.contributor.authorSchadendorf, D
dc.contributor.authorLorigan, Paul C
dc.contributor.authorIbrahim, N
dc.contributor.authorSuciu, S
dc.contributor.authorEggermont, A
dc.date.accessioned2018-09-10T21:07:51Z
dc.date.available2018-09-10T21:07:51Z
dc.date.issued2018
dc.identifier.citationPhase 3 randomized EORTC 1325-MG/KEYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage III melanoma. 2018, 14: 48-48 Asia Pac J Clin Oncolen
dc.identifier.urihttp://hdl.handle.net/10541/621219
dc.language.isoenen
dc.titlePhase 3 randomized EORTC 1325-MG/KEYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage III melanoma.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentFiona Stanley Hospital/University of Western Australia, Perth, Australiaen
dc.identifier.journalAsia-Pacific Journal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record